Table 4.

Effectiveness of ferric derisomaltose treatment over a median follow-up of 65 days, in the effectiveness population overall and by diagnosis

		n	Median (IQR)	p-value*
Hemoglobin, g/L
IDA	Baseline	76	10.7 (1.7)
	Follow-up	76	12.9 (1.5)
	Change from baseline	76	+ 2.0 (2.5)	< 0.0001
IDNA	Baseline	119	12.9 (1.2)
	Follow-up	118	13.4 (1.3)
	Change from baseline	118	+ 0.5 (1.0)	< 0.0001
Overall EP	Baseline	195	12.1 (2.3)
	Follow-up	194	13.2 (1.3)
	Change from baseline	194	+ 0.7 (1.5)	< 0.0001
Ferritin, μg/L
IDA	Baseline	65	10.0 (26.0)
	Follow-up	47	132.0 (183.0)
	Change from baseline	44	+ 121.0 (131.0)	< 0.0001
IDNA	Baseline	116	18.0 (17.8)
	Follow-up	97	149.0 (114.0)
	Change from baseline	94	+ 128.0 (115.5)	< 0.0001
Overall EP	Baseline	181	17.0 (21.0)
	Follow-up	144	144.0 (124.3)
	Change from baseline	138	+ 125.5 (126.0)	< 0.0001
Transferrin saturation (%)
IDA	Baseline	39	9.5 (16.0)
	Follow-up	22	25.0 (15.5)
	Change from baseline	21	+ 10.0 (14.7)	0.0007
IDNA	Baseline	75	21.0 (14.6)
	Follow-up	41	26.5 (17.7)
	Change from baseline	39	+ 5.3 (16.0)	0.0012
Overall EP	Baseline	114	17.1 (17.0)
	Follow-up	63	26.0 (18.1)
	Change from baseline	60	+ 8.5 (17.3)	< 0.0001

EP effectiveness population, IDA iron deficiency anemia, IDNA iron deficiency without anemia, IQR interquartile range

^*Non-parametric signed rank test